Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Vascular Graft Infections (VASGRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01821664
Recruitment Status : Recruiting
First Posted : April 1, 2013
Last Update Posted : May 6, 2015
Schweizerischer Nationalfonds
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
Background: Vascular grafts are increasingly implanted due to an increasing prevalence of atherosclerosis and diabetes, and about 1-6% of vascular procedures are complicated by infection. Mortality attributable to prosthetic vascular graft infections (PVGI) is high. However, there are almost no data regarding best treatment options of such complicated infections. Most recommendations are based on expert opinion and not on clinical trials or cohort observational data analyses. Evaluating infectious and other complications after vascular surgery procedures are important, and additionally, such studies may offer insights for quality improvement and improved patient outcomes. With the first aim investigators will establish an infrastructure for studying PVGI in Zurich. Investigators will take advantage of the Swissvasc registry, a central registry which collects preoperative, operative and discharge data regarding the index vascular surgical interventions. They will create a prospective observational cohort database of all patients who receive a vascular graft (peripheral, aortic, vein) at the University hospital of Zurich (VASGRA Cohort A). Patients with a PVGI will be included in VASGRA Cohort B and followed up using a flow chart with a focus on the course of this infectious complication. Additionally, investigators will establish a biobank with the collection of tissue- and blood samples of patients with PVGI. With the second aim researchers will investigate different diagnostic, clinical and therapeutic research questions nested in the VASGRA Cohort. Firstly, they will address epidemiological questions, such as: determine the incidence and outcome of complications after vascular graft placement; determine risk factors, best treatment strategies and outcome of PVGI, and determine the influence of different antibiotic regimens on the outcome of PVGI due to different bacterial pathogens. Secondly, investigators will determine the accuracy of different imaging techniques (PET/CT and MRI) for the diagnosis of PVGI, and their individual role for the assessment of treatment response. Thirdly, investigators will evaluate the bacterial diversity of vascular wound infections using 16s r-Ribonucleic acid (RNA)amplification, and investigators will explore whether this bacterial diversity does predict disease progression. Here, investigators will also study the impact of negative pressure wound therapy (NPWT) on bacterial diversity in the treatment course of PVGI. Fourthly, investigators will look for cut-off levels of relevant blood leucocytes count, C-reactive protein and procalcitonin raising suspicion of a PVGI. Lastly, investigators will look at histopathological features of excised vascular grafts. Expected value of the project: Results from the proposed study are an important contribution to the field, based on the large sample size, longitudinal design and by unifying clinical and epidemiological science. The very well characterized patient groups and the close connection between vascular surgeons, infectious disease specialists, specialists in nuclear medicine and microbiologist will help to investigate PVGI in depths. Investigators hope to be able to develop guidelines regarding best diagnostic modalities and treatment options in case of vascular graft infections. In the future we plan to examine bacteria retrieved from the PVGI in the laboratory in detail. The recovered bacteria will be examined for antimicrobial susceptibility and their capability to form biofilms. Furthermore investigators will examine how bacterial recovery form explanted grafts could be optimized.

Condition or disease Intervention/treatment
Prosthetic Vascular Graft Infection Device: Prosthetic vascular graft

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1800 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: Vascular Graft Infections - Epidemiology, Best Treatment Options, Imaging Modalities and Impact of Negative Pressure Wound Therapy
Study Start Date : May 2013
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Group/Cohort Intervention/treatment
Prosthetic vascular graft implantation, follow up Device: Prosthetic vascular graft
Implantation of a prosthetic vascular graft
Other Names:
  • Valsalva Graft, Gelwave TM
  • Subclavia Graft, Gelwave TM
  • Longer Ante-Flo Offset branch, Gelwave TM
  • Lupiae Branched Graft, Gelwave TM
  • 4 Branched Plexus, Gelwave TM
  • Bifurcate, Gelwave TM soft
  • Subclavia Graft straight, Gelwave TM soft
  • Intergard woven straight, Intervascular "Maquet Getinge Group"
  • Intergard woven hemabridge, Intervascular "Maquet Getinge Group"
  • Intergard woven Aortic Arch, Intervascular "Maquet Getinge Group"
  • Intergard Silver Knitted Bifurcation, Intervascular "Maquet Getinge Group"
  • Intergard Silver Knitted Straight, Intervascular "Maquet Getinge Group"
  • InterGard TM knitted Bifurcation, Intervascular "Maquet Getinge Group"
  • FlowLine Bipore r Heparin ePTFE Vascular Graft, Jotec r GmbH
  • ePTFE Vascular Graft Regular Wall flex, IMPRA r
  • ePTFE Vascular Graft Thin Wall flex, IMPRA r
  • ePTFE Vascular Graft Regular Wall straight, IMPRA r
  • Gore-Tex Stretch Vascular Graft standard Wall Eptfe, W.L. Gore & Associates, Inl

Primary Outcome Measures :
  1. Vascular graft infection [ Time Frame: within 10 years ]
    Persons are followed up after vascular graft surgery.

Secondary Outcome Measures :
  1. Bleeding [ Time Frame: 10 years ]
  2. Foreign body reaction [ Time Frame: 10 years ]
  3. All cause- mortality [ Time Frame: 10 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with a vascular surgery at the University hospital will be included in the study.

Inclusion criteria:

Control patients:

- Vascular graft surgery (peripheral, aortic, vein)

Case patients:

  • Patients with previous primary implantation of an aortic or peripheral vascular implant and suspicion of PVGI
  • Age >18 years
  • Written informed consent

Exclusion criteria:

  • Drug or alcohol abuse
  • Involvement in a conflicting clinical trial (investigational drug)
  • Inability to follow the procedures of the cohort, e.g. due to language problems, psychological disorders or dementia of the subject
  • Known or suspected non-compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01821664

Layout table for location contacts
Contact: Barbara Hasse, MD +41 (0)44 255 11 11

Layout table for location information
University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology Recruiting
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Schweizerischer Nationalfonds
Layout table for investigator information
Principal Investigator: Barbara Hasse, MD University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology
Additional Information:

Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: University of Zurich Identifier: NCT01821664    
Other Study ID Numbers: KEK-ZH-Nr. 2012-0583
First Posted: April 1, 2013    Key Record Dates
Last Update Posted: May 6, 2015
Last Verified: May 2015
Keywords provided by University of Zurich:
Prosthetic vascular graft infection
negative pressure wound therapy
antimicrobial therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Disease Attributes
Pathologic Processes
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action